Published in Drug Week, June 24th, 2005
The data were presented at the 41st annual meeting of the American Society of Clinical Oncology (ASCO) (Abstract #8125).
"This is the largest, randomized, head-to-head comparison of darbepoetin alfa dosed every 2 weeks to Epoetin alfa dosed weekly, as they are most often used in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.